miRagen Therapeutics' Chief Scientific Advisor to Give Plenary Lecture at Joint Meeting of the American Society for Clinical Investigation and the Association of American Physicians
Lecture to Focus on Role of microRNA Biology in the Progression of Cardiovascular and Muscle Disease and the Potential for Therapeutic Intervention
BOULDER, Colo.--(BUSINESS WIRE)--Apr 23, 2010 - miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that its Chief Scientific Advisor and Co-Founder, Eric N. Olson, Ph.D., will give a plenary lecture at the joint meeting of the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). The lecture, which is scheduled to take place at 10:15 a.m. on Saturday, April 24, 2010, at The Fairmont Chicago, will highlight recent miRNA discoveries in a variety of areas being pursued by the company.
“I am glad to be able to present our findings to this group,” said Dr. Olson. “Certain cardiovascular and muscle disorders represent areas of high unmet medical need for patients, and understanding the pivotal role that microRNAs play in several underlying disease processes presents a promising avenue for the development of novel therapies to help those afflicted. As our data demonstrate, miRNAs have a profound impact on disease progression, and we are optimistic that these discoveries may be translated into meaningful treatments.”
About microRNAs: MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are responsible for many diseases. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets of unprecedented power.
About miRagen Therapeutics: miRagen Therapeutics, Inc., was founded in 2007 to develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. Only recently discovered, microRNAs are short, single-stranded RNA molecules encoded in the genome that regulate gene expression and play a vital role in influencing cardiovascular and muscle disease. Cardiovascular disease is the leading cause of death globally and represents an enormous burden on global healthcare systems. Principally funded through venture capital investments, miRagen combines world recognized leadership in cardiovascular medicine with unprecedented in-house expertise in microRNA biology and chemistry. For more information, please visit www.miragentherapeutics.com.
Contact: For miRagen Therapeutics, Inc.
Scout Investor Relations
Anna Sussman, 303-907-5358
Posted: April 2010